Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OHFVU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NY920-P1-L12-P2
|
|||||
| Synonyms |
NY920-P1-L12-P2
Click to Show/Hide
|
|||||
| Organization |
NOVARTIS AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
NY920
|
Antibody Info | ||||
| Antigen Name |
CD48 antigen (CD48)
|
Antigen Info | ||||
| Payload Name |
P2 payload
|
Payload Info | ||||
| Linker Name |
L12 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.037 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.217 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in NCI-H929
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.305 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.38 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in KMS-21-BM
|
||||
| In Vitro Model | Multiple myeloma | KMS-21-BM cells | CVCL_2991 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 1 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in Ke97
|
||||
| In Vitro Model | Bladder carcinoma | Ke97 cells | CVCL_3386 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 5 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in AMO-1
|
||||
| In Vitro Model | Multiple myeloma, Plasma cell myeloma | AMO-1 cells | CVCL_1806 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in WSU-DLCL2
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
NY920-P1-L12-P2 was tested in MOLP-8
|
||||
| In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||